These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 27107511)
1. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis. Del Papa N; Zaccara E Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):756-69. PubMed ID: 27107511 [TBL] [Abstract][Full Text] [Related]
2. [B cell abnormalities and therapeutic strategies in systemic sclerosis]. Yoshizaki A Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935 [TBL] [Abstract][Full Text] [Related]
10. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905 [TBL] [Abstract][Full Text] [Related]
11. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality? Jimenez SA; Piera-Velazquez S Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760 [TBL] [Abstract][Full Text] [Related]
12. Clinical Trial Design Issues in Systemic Sclerosis: an Update. Gordon JK; Domsic RT Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381 [TBL] [Abstract][Full Text] [Related]
13. Targeting vascular disease in systemic sclerosis. Kowal-Bielecka O Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):401-7. PubMed ID: 17214586 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis. Asano Y Int J Biochem Cell Biol; 2015 Oct; 67():86-91. PubMed ID: 26055516 [TBL] [Abstract][Full Text] [Related]
15. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines. Hasegawa M; Takehara K Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279 [TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. Hasegawa M; Fujimoto M; Takehara K; Sato S J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984 [TBL] [Abstract][Full Text] [Related]
17. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis. Farina N; Campochiaro C; Lescoat A; Benanti G; De Luca G; Khanna D; Dagna L; Matucci-Cerinic M Expert Rev Clin Immunol; 2023; 19(9):1131-1142. PubMed ID: 37366065 [TBL] [Abstract][Full Text] [Related]
19. [A Uuifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 - the development of a new animal model of systemic sclerosis -]. Asano Y Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):475-87. PubMed ID: 25748132 [TBL] [Abstract][Full Text] [Related]